This article is more than 5 years old. Information may no longer be current.

Parion Sciences initiates phase 2 trial of P-321 ophthalmic solution for dry eye disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patient enrollment is underway for a phase 2 clinical trial of P-321 ophthalmic solution for the treatment of dry eye disease, according to a press release from Parion Sciences.

The study, P-321-202, will assess the impact of the ophthalmic solution on dry eye symptoms, as well as safety and clinical signs of dry eye.

Approximately 60 patients are expected to be enrolled in the randomized, double-masked, parallel group study of P-321 compared with placebo in patients with dry eye disease over a period of 28 days.

P-321 is a potent inhibitor of the epithelial sodium channels of the ocular surface, designed to restore the tear film on the ocular surface, the release said.